Clinical trials: Patients With Advanced Solid Tumors
Solid Tumors
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies.
- Trial name
- NCT02620839
- Testing
- Alpelisib, Cisplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Pamela Munster
Advanced Malignant Solid Tumor
PRL3-Zumab in Patients With Advanced Solid Tumors
This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
- Trial name
- China Phase II (NCT07541001)
- Testing
- PRL3-ZUMAB
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
This trial is an open, two-stage, multi-center, phase II clinical trial to evaluate the efficacy and safety of Utidelone in advanced solid tumors (excluding breast cancer, lung cancer, and colorectal cancer) that have failed…
- Trial name
- NCT04911907
- Testing
- utidelone injection
- Where
- 3 sites in China
- Volunteers
- 126 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Advanced Solid Tumor, Recurrent Endometrial Cancer
Study of ART0380 in Patients With Biologically Selected Solid Tumors
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein…
- Conditions
- Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
- Trial name
- ARTIST (NCT05798611)
- Testing
- ART0380
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Artios Pharma Ltd
Tumors, Non Hodgkin's Lymphoma
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.
- Trial name
- NCT00323934
- Testing
- MGCD0103
- Where
- 3 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Mirati Therapeutics Inc.
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Advanced Solid Tumors Patients
Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
This study includes two parts, different part has different administration frequencies of SSGJ-706.
- Trial name
- NCT06533605
- Testing
- SSGJ-706
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neoplasms
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or…
- Trial name
- NCT02219724
- Testing
- MOXR0916
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 174 people
- Sponsor
- Genentech, Inc.
Neoplasms，Non-Small Cell Lung Cancer
Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer
The purpose of this study is to assess the pharmacokinetics，safety and tolerability of Hemay020 and to determine the recommended dose for future Phase II study as well as to obtain preliminary information on the efficacy of…
- Trial name
- NCT02467569
- Testing
- Hemay020
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Advanced Malignant Solid Tumors, TGCT
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose…
- Trial name
- NCT05277454
- Testing
- HMPL-653
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hutchison Medipharma Limited
Advanced Solid Tumors
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
- Trial name
- NCT03113188
- Testing
- CBP501
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- CanBas Co. Ltd.
Advanced Solid Tumor, Hematological Malignancy
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
- Trial name
- NCT06225856
- Testing
- YY201
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
This is a single arm, open-label, phase I dose finding study, followed by a phase II expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of 33 patients with refractory…
- Conditions
- Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT05035745
- Testing
- Talazoparib, Selinexor
- Where
- Singapore
- Volunteers
- 63 people
- Sponsor
- National University Hospital, Singapore
Solid Tumor
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT01875705
- Testing
- GDC-0994
- Where
- 4 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.
- Trial name
- NCT03700294
- Testing
- ADCT-601
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ADC Therapeutics S.A.
Neoplasms
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
The primary objective of this trial is to determine the Maximum Tolerated Dose (MTD) of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly.
- Trial name
- NCT00998296
- Testing
- BIBW 2992, BIBF 1120
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth…
- Trial name
- NCT00483366
- Testing
- capecitabine, gemcitabine hydrochloride, imatinib mesylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
Melanoma Neoplasms
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic…
- Trial name
- NCT00516802
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.